Literature DB >> 3083205

Hyperglycemia as a cause of diabetic retinopathy.

R L Engerman, T S Kern.   

Abstract

Diabetes mellitus is marked by hyperglycemia and a variety of other metabolic disorders. The significance of hyperglycemia in the pathogenesis of diabetic retinopathy has proven difficult to evaluate in patients. Diabetic dogs are known to develop retinal lesions morphologically identical to those typical of diabetes in man, provided hyperglycemia in the animal is allowed to persist at least for many months and usually for 3 to 5 years. The development of retinopathy in this animal model can be inhibited by careful improvement of diabetic (glycemic) control. Comparable retinopathy has recently been found to develop in nondiabetic dogs as a result of experimental galactosemia of several years' duration. Included in this retinopathy and in the retinopathy of diabetic patients and dogs as well are saccular capillary aneurysms, hemorrhages, nonperfused or acellular vessels, varicose vessels, and loss of capillary pericytes. Retinal capillary basement membrane has been measured (to date) in two dogs that had been galactosemic for 5 years, and it was found to be significantly thicker than in normal dogs (P less than 0.01). Many metabolic abnormalities typical of diabetes are absent from galactosemic dogs. Unlike diabetic dogs, the blood levels of glucose, nonesterified fatty acids, branched-chain amino acids, and fibrinogen are not elevated in the galactosemic dogs, and their serum insulin concentration seems normal. Excessive blood hexose itself appears to be an important determinant of retinopathy. One possible mechanism by which excessive blood hexose might produce retinopathy involves the polyol pathway.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3083205     DOI: 10.1016/0026-0495(86)90182-4

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  22 in total

1.  miR-15a/16 inhibits TGF-beta3/VEGF signaling and increases retinal endothelial cell barrier proteins.

Authors:  Eun-Ah Ye; Li Liu; Jena J Steinle
Journal:  Vision Res       Date:  2017-08-07       Impact factor: 1.886

2.  Effect of the nonenzymatic glycosylation of high density lipoprotein-3 on the cholesterol ester transfer protein activity.

Authors:  B Lemkadem; D Loiseau; G Larcher; Y Malthiery; F Foussard
Journal:  Lipids       Date:  1999-12       Impact factor: 1.880

Review 3.  Cardiomyopathy associated with noninsulin-dependent diabetes.

Authors:  S W Schaffer
Journal:  Mol Cell Biochem       Date:  1991-09-18       Impact factor: 3.396

4.  Spectroscopic Doppler analysis for visible-light optical coherence tomography.

Authors:  Xiao Shu; Wenzhong Liu; Lian Duan; Hao F Zhang
Journal:  J Biomed Opt       Date:  2017-10       Impact factor: 3.170

Review 5.  Dietary hyperglycemia, glycemic index and metabolic retinal diseases.

Authors:  Chung-Jung Chiu; Allen Taylor
Journal:  Prog Retin Eye Res       Date:  2010-09-22       Impact factor: 21.198

6.  Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory.

Authors:  Pooi-See Chan; Mamta Kanwar; Renu A Kowluru
Journal:  J Diabetes Complications       Date:  2008-12-03       Impact factor: 2.852

7.  Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial.

Authors:  J M van Gerven; J P Boot; H H Lemkes; J A van Best
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

8.  Diabetic retinopathy: quantitative variation in capillary basement membrane thickening in arterial or venous environments.

Authors:  A W Stitt; H R Anderson; T A Gardiner; D B Archer
Journal:  Br J Ophthalmol       Date:  1994-02       Impact factor: 4.638

Review 9.  Galactose toxicity in animals.

Authors:  Kent Lai; Louis J Elsas; Klaas J Wierenga
Journal:  IUBMB Life       Date:  2009-11       Impact factor: 3.885

10.  Sirt1, a negative regulator of matrix metalloproteinase-9 in diabetic retinopathy.

Authors:  Renu A Kowluru; Julia M Santos; Qing Zhong
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-06-03       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.